Cited by 208Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and TreatmentCancer Genomics and Diagnostics

Lead-time trajectory of CA19-9 as an anchor marker for pancreatic cancer early detection

Open access
Fahrmann, Johannes F., Schmidt, C. Max, Mao, Xiangying, Irajizad, Ehsan, Loftus, Maureen, Zhang, Jinming, Patel, Nikul, Vykoukal, Jody +19 more·2021·Gastroenterology

Abstract

Background & aims There is substantial interest in liquid biopsy approaches for cancer early detection among subjects at risk, using multi-marker panels. CA19-9 is an established circulating biomarker for pancreatic cancer; however, its relevance for pancreatic cancer early detection or for monitoring subjects at risk has not been established.Methods CA19-9 levels were assessed in blinded sera from 175 subjects collected up to 5 years before diagnosis of pancreatic cancer and from 875 matched controls from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. For comparison of performance, CA19-9 was assayed in blinded independent sets of samples collected at diagnosis from 129 subjects with resectable pancreatic cancer and 275 controls (100 healthy subjects; 50 with chronic pancreatitis; and 125 with noncancerous pancreatic cysts). The complementary value of 2 additional protein markers, TIMP1 and LRG1, was determined.Results In the PLCO cohort, levels of CA19-9 increased exponentially starting at 2 years before diagnosis with sensitivities reaching 60% at 99% specificity within 0 to 6 months before diagnosis for all cases and 50% at 99% specificity for cases diagnosed with early-stage disease. Performance was comparable for distinguishing newly diagnosed cases with resectable pancreatic cancer from healthy controls (64% sensitivity at 99% specificity). Comparison of resectable pancreatic cancer cases to subjects with chronic pancreatitis yielded 46% sensitivity at 99% specificity and for subjects with noncancerous cysts, 30% sensitivity at 99% specificity. For prediagnostic cases below cutoff value for CA19-9, the combination with LRG1 and TIMP1 yielded an increment of 13.2% in sensitivity at 99% specificity (P = .031) in identifying cases diagnosed within 1 year of blood collection.Conclusion CA19-9 can serve as an anchor marker for pancreatic cancer early detection applications.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1053/j.gastro.2020.11.052

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • CA19-9 elevations can be observed in plasma samples obtained before diagnosis, suggesting a potential window for early detection.

    “CA19–9 elevations can be observed in plasma samples obtained in the pre-diagnostic setting, suggesting a potential window of opportunity for early detection38.”

    From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [38]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 56 references couldn’t be matched to a known paper.

Cited by

Sorted by citations

Authors
Fahrmann, J. F., Schmidt, C. M., Mao, X., Irajizad, E., Loftus, M., Zhang, J., Patel, N., Vykoukal, J., Dennison, J. B., Long, J. P., Do, K.-A., Zhang, J., Chabot, J. A., Kluger, M. D., Kastrinos, F., Brais, L., Babic, A., Jajoo, K., Lee, L. S., Clancy, T. E., Ng, K., Bullock, A., Genkinger, J., Yip-Schneider, M. T., Maitra, A., Wolpin, B. M., & Hanash, S.
Affiliations
  • The University of Texas MD Anderson Cancer Center (US)
  • Indiana University School of Medicine (US)
  • Harvard University (US)
  • Columbia University Irving Medical Center (US)
  • Brigham and Women's Hospital (US)
  • Beth Israel Deaconess Medical Center (US)
Corresponding author
Hanash, Samir
Venue
Gastroenterology
Publisher
Elsevier BV
Published
2021-03
Volume
160
Issue
4
Pages
1373-1383.e6
ISSN
0016-5085 (ISSN-L)
OpenAlex
W3110895646
Cited by
208
References
56
Citations by year
2026: 37 · 2025: 52 · 2024: 40 · 2023: 37 · 2022: 30 · 2021: 12
FWCI
7.13
Type
journal article
Language
en
Open access
Locations
  • Gastroenterology (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • IUScholarWorks (Indiana University) (submittedVersion)
  • Purdue University Indianapolis (Indiana University) (submittedVersion)
Funders
  • National Institutes of Health
  • National Cancer Institute
  • Pancreatic Cancer Action Network
  • Lustgarten Foundation
  • University of Texas MD Anderson Cancer Center
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
Keywords
CA19-9, pancreatic cancer, early detection, liquid biopsy, circulating tumor markers, TIMP-1, LRG1, multimarker panels, pre-diagnostic biomarkers, chronic pancreatitis, pancreatic cysts, PLCO Cancer Screening Trial
MeSH terms
Liquid Biopsy, Aged, Diagnosis, Differential, Feasibility Studies, Female, Humans, Male, Mass Screening, Middle Aged, Pancreatic Cyst, Pancreatic Neoplasms, Sensitivity and Specificity, United States, CA-19-9 Antigen, Pancreatitis, Chronic, Early Detection of Cancer, Healthy Volunteers

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review